REG - N4 Pharma PLC - Granting of Patents

N4 PharmaAnnouncement

31/01/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220131:nRSe0490Aa&default-theme=true

RNS Number : 0490A  N4 Pharma PLC  31 January 2022

31 January 2022

N4 Pharma Plc

("N4 Pharma" or the "Company")

Granting of Patents

N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing
Nuvec®, a novel delivery system for cancer treatments and vaccines, announces
that the University of Queensland has informed the Company that it has been
notified by the US patent attorney of the granting of its patent application
in relation to Nuvec® in the United States and by the Chinese authorities of
the granting of a patent in China. N4 Pharma has the exclusive worldwide
rights to Nuvec® for therapeutic uses in humans and animals.

The granted patent in the USA will specifically cover the matter of
composition of the nanoparticle made using a broad description of the
manufacturing process used by the Company. The University of Queensland has
also informed the Company it will file a continuation patent application in
the USA for a matter of composition patent independent of the manufacturing
process to match the patents granted in Europe, Japan, Australia and China.

Nigel Theobald, Chief Executive Officer of the Company, commented: "We are
delighted to receive notification of this allowance to grant our licensed
patent in these critical and influential markets.

"The granting of this USA nanoparticle patent using a broad description of the
manufacturing process adds to the other granted patents giving us strong
intellectual property protection in the key territories across the world which
is a vital component for potential licensing deals"

 

The information contained within this announcement is deemed by the Company to
constitute inside information as stipulated under the Market Abuse Regulations
(EU) No. 596/2014 which has been incorporated into UK law by the European
Union (Withdrawal) Act 2018.

Enquiries:

 N4 Pharma Plc                                       Via IFC Advisory

 Nigel Theobald, CEO

 Luke Cairns, Executive Director

 SP Angel Corporate Finance LLP                      Tel: +44 (0)20 3470 0470

 Nominated Adviser and Joint Broker

 Matthew Johnson/Caroline Rowe (Corporate Finance)

 Vadim Alexandre/Rob Rees (Corporate Broking)

 Turner Pope Investments (TPI) Limited               Tel: +44 (0)20 3657 0050

 Joint Broker

 Andy Thacker

 IFC Advisory Limited                                Tel: +44 (0)20 3934 6630

 Financial PR

 Graham Herring

 Zach Cohen

 

About N4 Pharma

N4 Pharma is a specialist pharmaceutical company developing a novel delivery
system for cancer and vaccine treatments using its unique silica nanoparticle
delivery system called Nuvec®.

N4 Pharma's business model is to partner with companies developing novel
antigens for cancer and vaccine treatments to use Nuvec® as the delivery
vehicle to get their antigen into cells to express the protein needed for the
required immunity. As these products progress through pre clinical and
clinical programs, N4 Pharma will seek to receive up front payments, milestone
payments and ultimately royalty payments once products reach the market.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCBKFBNOBKDPDB